TheZEPROJECTBack to catalogue

Safety · Disclaimer

Read this before anything else

THE ZEPROJECT is an educational catalogue of 20 research compounds. It exists to make mechanisms legible — not to sell, prescribe, dose or encourage self-experimentation.

Research-use framing

Everything in the catalogue is presented as research literature: mechanisms, receptor targets and reported outcomes. Nothing on this site is offered for human consumption, and no listing implies regulatory approval in your country.

A doctor decides, not a catalogue

Suitability depends on your labs, medications, history and goals. We route every interested reader to a licensed physician rather than publishing dosing schedules or protocols.

Sourcing and handling

Purity, sterility, reconstitution and cold-chain handling materially change risk. Third-party analysis (HPLC and mass spec) and correct storage are non-negotiable before anything is considered.

Known risks by group

Incretin & metabolic (Tirzepatide, Retatrutide, Cagrilintide)

  • Nausea, vomiting, constipation and reflux, most often during dose escalation
  • Gallbladder events, pancreatitis and dehydration-related injury
  • Lean-mass loss and micronutrient shortfalls when intake drops sharply
  • Hypoglycaemia risk rises alongside insulin or sulfonylureas

Growth-axis & performance (Tesamorelin, Ipamorelin, Kisspeptin, PT-141)

  • Water retention, joint discomfort, paraesthesia and insulin-sensitivity shifts
  • Unknown effect on undiagnosed malignancy — a hard contraindication
  • PT-141: transient nausea, flushing and blood-pressure changes
  • Hormonal-axis interventions can disturb fertility and menstrual cycles

Repair, cellular & cognitive (BPC 157, TB500, GHK-Cu, KPV, SS-31, MOTS-c, Semax, Selank, Epithalon, 5-Amino-1MQ, blends)

  • Injection-site reactions, infection and injury masking during rehab
  • Angiogenic and growth-promoting signalling is not appropriate with active or suspected cancer
  • Blends (Wolverine, GLOW, KLOW) multiply variables — a reaction is hard to attribute
  • Long-term human safety data is limited to absent for most of this group

Do not proceed without a physician if any apply

  • Pregnancy, breastfeeding, or trying to conceive
  • Active, suspected or recently treated cancer
  • Personal or family history of medullary thyroid carcinoma or MEN2 (incretins)
  • Pancreatitis, gallbladder disease, gastroparesis or severe reflux
  • Type 1 diabetes, or type 2 on insulin/sulfonylureas without supervision
  • Significant kidney, liver or cardiovascular disease
  • Uncontrolled blood pressure (relevant to PT-141)
  • Under 18, or an eating disorder history without specialist oversight

Full disclaimer

The content on THE ZEPROJECT is provided for informational and educational purposes only. It is not medical advice, diagnosis or treatment, and it does not create a doctor–patient relationship. Statements about compounds summarise published preclinical and clinical literature and have not been evaluated by any regulatory agency.

Many compounds described here are not approved for human use in most jurisdictions, and some are prohibited in competitive sport under WADA rules. Nothing on this site is an offer to sell, supply or distribute any substance for human consumption. You are responsible for the laws that apply where you live.

Never start, stop or change a medication or protocol based on this site. Speak with a licensed physician who can review your history, medications and bloodwork. If you experience a severe reaction — chest pain, difficulty breathing, persistent vomiting, severe abdominal pain, or signs of an allergic reaction — seek emergency care immediately.

To the fullest extent permitted by law, THE ZEPROJECT disclaims liability for any loss or harm arising from use of, or reliance on, this information.

Speak with a doctorReturn to the catalogue